OKYO Pharma Ltd. (OKYO) Financials
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | MAR 2026 | MAR 2025 | MAR 2024 | MAR 2023 | MAR 2022 |
|---|---|---|---|---|---|
| Revenues | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$8 | -$7 | -$16 | -$13 | -$5 |
| Non-Operating | |||||
| Net Interest Expense | -$0 | -$1 | -$1 | -$0 | $0 |
| Income Tax Expense | $0 | -$3 | $0 | -$0 | -$1 |
| Net Income | |||||
| Net Income | -$9 | -$5 | -$17 | -$13 | -$4 |
| Per Share Data | |||||
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Basic) | -$0.24 | -$0.12 | -$0.57 | -$0.61 | -$0.36 |
| EPS (Diluted) | -$0.24 | -$0.12 | -$0.57 | -$0.61 | -$0.36 |
| Shares Outstanding | 37.4M | 39.5M | 29.3M | 22.3M | 11.2M |
OKYO Pharma (OKYO) financials: revenue, profit and margins
OKYO Pharma (OKYO) generated about $0.00 in revenue and -$9 million in net income over the trailing twelve months. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is OKYO Pharma's (OKYO) revenue?+
OKYO Pharma generated about $0.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is OKYO Pharma profitable?+
OKYO Pharma reported about -$9 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.